New data from a real-life study show that afatinib followed by osimertinib provided a median overall survival of up to almost four years (45.7 months) … Read more

An international collaboration, using data from more than 100,000 women with breast cancer from 58 epidemiological studies worldwide, has found that the use of menopausal … Read more

Bone cancer is one of the less frequent neoplasms, but just as deadly as the rest of the malignant tumors. According to data from the … Read more

The European Commission has approved the combination of Tecentriq (atezolizumab) plus chemotherapy (Abraxane) for the treatment of patients with locally unresectable or metastatic advanced breast … Read more

Researchers of Molecular Therapy Research Group of the cancer of the Hospital del Mar Institute of Medical Research (IMIM) and doctors of the Hospital del … Read more

Researchers at the Josep Carreras Leukemia Research Institute have described an epigenetic lesion that causes in breast cancer the “aberrant activity” of a hundred genes … Read more

Scientists at the Georgetown University Medical Center (United States) have discovered a mechanism that could explain why some cancers do not respond to a widely … Read more

Spanish researchers from Integral Cancer Center Clara Campal HM CIOCC They have defined for the first time a series of molecular markers that identify those … Read more

The US drug agency (FDA) has approved darolutamide, a non-steroidal androgen receptor antagonist, under the trade name of Nubeqa. The FDA-approved indication is the treatment … Read more

Researchers of the Faculty of Medicine of the University of Virginia (United States) have identified “We have discovered a new non-coding RNA that may be … Read more